form8k_mar09financialinfo.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
________________
FORM
8-K
________________
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): April 20, 2009
ATHEROGENICS,
INC.
(Exact
Name of Registrant as Specified in its Charter)
|
Georgia
|
0-31261
|
58-2108232
|
|
(State
or other jurisdiction
|
(Commission
|
(I.R.S.
Employer
|
|
of
incorporation)
|
File
Number)
|
Identification
Number)
|
8995
Westside Parkway
Alpharetta,
GA 30009
(Address
of principal executive offices)
Registrant's
telephone number, including area code (678) 336-2500
_________________
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2.
below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01 Other Events
AtheroGenics,
Inc. (the “Company”) is required to file monthly operating reports in the United
States Bankruptcy Court for the Northern District of Georgia (the “Bankruptcy
Court”). On April 20, 2009, the Company filed its monthly operating report for
the month ended March 31, 2009 with the Bankruptcy Court. Selected
financial information for the month of March included in the monthly operating
report (the “Selected Financial Information”) is attached hereto as Exhibit
99.1.
The information contained in the
Selected Financial Information is preliminary and subject to revision, and the
Company cautions readers not to place undue reliance upon this information. The
Selected Financial Information is unaudited, in a format prescribed by
applicable bankruptcy laws, and has not been prepared in conformity with
generally accepted accounting principles. The information in the Selected
Financial Information might not be indicative of the Company’s financial
condition or operating results for the period that would be reflected in the
Company’s financial statements or in a periodic report filed pursuant to the
Securities Exchange Act of 1934, as amended. The information set forth in the
Selected Financial Information should not be viewed as indicative of future
results and should not be used for investment purposes.
Item
9.01. Financial Statements and Exhibits.
The
following exhibit is furnished as part of this current report on Form
8-K.
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
99.1
|
–
|
Selected
Financial Information
|
SIGNATURE
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, hereunto duly
authorized.
|
|
|
ATHEROGENICS,
INC.
|
|
|
|
|
|
Date: April
20, 2009
|
|
By:/s/CHARLES A.
DEIGNAN
|
|
|
|
Charles
A. Deignan
|
|
|
|
President,
Chief Financial Officer
|
|
|
|
and
Secretary
|
EXHIBIT
INDEX
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
99.1
|
–
|
Selected
Financial Information
|